Antonio Nicolini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Antonio Nicolini has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
Andrea Lovaria
4 shared publications- Angelo Sangiovanni
Division of Gastroenterology and Hepatology, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy
4 shared publications Silvia Crespi
Radiology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy
4 shared publicationsLaura Martinetti
Radiology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy
3 shared publicationsA. Lovaria
Vascular Interventional Radiology Unit (A.N., A.L., D.M.), Policlinico-University Hospital IRCCS, Milan, Italy
2 shared publicationsA. Sangiovanni
2 shared publications
Latest Publications
- Open Access
- 1 July 2020
- Published by Elsevier in Ultrasound in Medicine & Biology
- Vol. 46 (7) , 1641-1650
The Role of Spleen and Liver Elastography and Color-Doppler Ultrasound in the Assessment of Transjugular Intrahepatic Portosystemic Shunt Function
- 1 July 2020
- Published by Elsevier in Ultrasound in Medicine & Biology
- Vol. 46 (7) , 1641-1650
Open AccessThe Role of Spleen and Liver Elastography and Color-Doppler Ultrasound in the Assessment of Transjugular Intrahepatic Portosystemic Shunt Function
- Open Access
- 13 June 2015
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 21 (10) , 1259-1269
Transarterial chemoembolization with drug‐eluting beads is effective for the maintenance of the Milan‐in status in patients with a small hepatocellular carcinoma
Transarterial chemoembolization (TACE) is the standard of care for the treatment of patients with an intermediate (Barcelona Clinic Liver Cancer [BCLC] B) hepatocellular carcinoma and to bridge patients with an early cancer to liver transplantation (LT). We explored the efficacy of TACE with drug‐eluting beads (DEB) in BCLC A patients. Included are all BCLC A patients unsuitable for resection or locoregional ablation who underwent a DEB TACE between 2006 and 2012. Treatment was carried out “a la demande” until complete tumor devascularization or progression beyond Milan criteria. In patients with a complete response (CR), a contrast computed tomography (CT) scan was repeated at 3‐month intervals during the first 2 years and then every 6 months alternating with abdominal ultrasound in the subsequent 3 years. Fifty‐five patients had 79 tumor nodules ranging 7 to 50 mm; 32 (58%) achieved a CR that was maintained up to 4 and 7 months in 21 (38%) and 17 (31%) patients, respectively. The 24‐ and 36‐month tumor‐free survivals were 21% and 9%, respectively. The overall cumulative progression beyond Milan criteria at 3, 6, 12, and 24 months was 2%, 5%, 30%, and 54%. LT eligibility was maintained for a median of 19 months (range, 2‐63 months). CR to first TACE was the strongest independent predictor of Milan‐in maintenance. In conclusion, DEB TACE may effectively bridge patients with an early cancer to LT, and a CR to the first procedure may guide patient prioritization during the waiting list.Liver Transpl 21:1259‐1269, 2015. © 2015 AASLD.
- 13 June 2015
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 21 (10) , 1259-1269
Open AccessTransarterial chemoembolization with drug‐eluting beads is effective for the maintenance of the Milan‐in status in patients with a small hepatocellular carcinoma
Transarterial chemoembolization (TACE) is the standard of care for the treatment of patients with an intermediate (Barcelona Clinic Liver Cancer [BCLC] B) hepatocellular carcinoma and to bridge patients with an early cancer to liver transplantation (LT). We explored the efficacy of TACE with drug‐eluting beads (DEB) in BCLC A patients. Included are all BCLC A patients unsuitable for resection or locoregional ablation who underwent a DEB TACE between 2006 and 2012. Treatment was carried out “a la demande” until complete tumor devascularization or progression beyond Milan criteria. In patients with a complete response (CR), a contrast computed tomography (CT) scan was repeated at 3‐month intervals during the first 2 years and then every 6 months alternating with abdominal ultrasound in the subsequent 3 years. Fifty‐five patients had 79 tumor nodules ranging 7 to 50 mm; 32 (58%) achieved a CR that was maintained up to 4 and 7 months in 21 (38%) and 17 (31%) patients, respectively. The 24‐ and 36‐month tumor‐free survivals were 21% and 9%, respectively. The overall cumulative progression beyond Milan criteria at 3, 6, 12, and 24 months was 2%, 5%, 30%, and 54%. LT eligibility was maintained for a median of 19 months (range, 2‐63 months). CR to first TACE was the strongest independent predictor of Milan‐in maintenance. In conclusion, DEB TACE may effectively bridge patients with an early cancer to LT, and a CR to the first procedure may guide patient prioritization during the waiting list.Liver Transpl 21:1259‐1269, 2015. © 2015 AASLD.
- 2 May 2014
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 43 (5) , 602-604
Conservative treatment of giant uterine artery pseudoaneurysm
- 2 May 2014
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 43 (5) , 602-604
Conservative treatment of giant uterine artery pseudoaneurysm
- 1 April 2014
- Published by Elsevier in Journal of Hepatology
- Vol. 60 (1) , S405
P991 CHEMOEMBOLIZATION OF HEPATOCELLULAR CARCINOMA WITH M1 DRUG ELUTING BEADS: SAFETY AND EFFECTIVENESS
- 1 April 2014
- Published by Elsevier in Journal of Hepatology
- Vol. 60 (1) , S405
P991 CHEMOEMBOLIZATION OF HEPATOCELLULAR CARCINOMA WITH M1 DRUG ELUTING BEADS: SAFETY AND EFFECTIVENESS
- 1 February 2013
- Published by Elsevier in Digestive and Liver Disease
- Vol. 45, S42
F-36 Transarterial chemoembolization with drug-eluting beads (DEB TACE) for BCLC-A hepatocellular carcinoma (HCC): a radical option?
- 1 February 2013
- Published by Elsevier in Digestive and Liver Disease
- Vol. 45, S42
F-36 Transarterial chemoembolization with drug-eluting beads (DEB TACE) for BCLC-A hepatocellular carcinoma (HCC): a radical option?
- 14 June 2011
- Published by Informa Healthcare in Expert Opinion on Drug Delivery
- Vol. 8 (8) , 1071-1084
Drug delivery embolization systems: a physician's perspective
(2011). Drug delivery embolization systems: a physician's perspective. Expert Opinion on Drug Delivery: Vol. 8, No. 8, pp. 1071-1084. doi: 10.1517/17425247.2011.590472
- 14 June 2011
- Published by Informa Healthcare in Expert Opinion on Drug Delivery
- Vol. 8 (8) , 1071-1084
Drug delivery embolization systems: a physician's perspective
(2011). Drug delivery embolization systems: a physician's perspective. Expert Opinion on Drug Delivery: Vol. 8, No. 8, pp. 1071-1084. doi: 10.1517/17425247.2011.590472
- 9 September 2008
- Published by Springer Nature in La radiologia medica
- Vol. 113 (7) , 1008-1017
Role of transjugular liver biopsy in the diagnostic and therapeutic management of patients with severe liver disease
This study sought to assess the diagnostic yield, the impact on treatment and the safety of transjugular liver biopsy.
- 9 September 2008
- Published by Springer Nature in La radiologia medica
- Vol. 113 (7) , 1008-1017
Role of transjugular liver biopsy in the diagnostic and therapeutic management of patients with severe liver disease
This study sought to assess the diagnostic yield, the impact on treatment and the safety of transjugular liver biopsy.
- 12 August 2008
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 31 (6) , 1141-1149
Transarterial Chemoembolization for Hepatocellular Carcinoma with Drug-Eluting Microspheres: Preliminary Results from an Italian Multicentre Study
The purpose of this article is to present the early results of a multicentre trial using HepaSphere microspheres loaded with chemotherapeutic agents for transarterial chemoembolization (TACE) in patients with unresectable hepatocellular carcinoma. From December 2005 to March 2007, 50 patients (36 male and 14 female, mean age 68.4 years) were treated by selective TACE using HepaSphere microspheres loaded with doxorubicin or epirubicin. The diameter of the treated lesions ranged from 20 to 100 mm (mean 42.5; maximum of 4 tumor nodules). Tumor response was evaluated by computed axial tomography according to the World Health Organization criteria as modified by the European Association for the Study of Liver Diseases. All of the procedures were technically successful, and there were no major complications. At 1-month follow-up, complete tumor response was observed in 24 of 50 (48%), partial response in 18 of 50 (36%), and stable disease in 8 of 50 (16%) patients, and there were no cases of disease progression. At 6-month follow-up (31 of 50 patients), complete tumor response was obtained in 16 of 31 (51.6%), partial response in 8 of 31 (25.8%), and progressive disease in 7 of 31 (22.6%) patients. Within the initial 9-month follow-up, TACE with HepaSphere was successfully repeated twice in 3 patients, whereas 3 patients underwent the procedure 3 times. Our initial multicentre experience demonstrates that TACE using HepaSphere is feasible, is well tolerated, has a low complication rate, and is associated with promising tumor response. When complete tumor response in not achieved, additional treatments can be performed without difficulties. Longer follow-up on larger series is mandatory to confirm these preliminary results.
- 12 August 2008
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 31 (6) , 1141-1149
Transarterial Chemoembolization for Hepatocellular Carcinoma with Drug-Eluting Microspheres: Preliminary Results from an Italian Multicentre Study
The purpose of this article is to present the early results of a multicentre trial using HepaSphere microspheres loaded with chemotherapeutic agents for transarterial chemoembolization (TACE) in patients with unresectable hepatocellular carcinoma. From December 2005 to March 2007, 50 patients (36 male and 14 female, mean age 68.4 years) were treated by selective TACE using HepaSphere microspheres loaded with doxorubicin or epirubicin. The diameter of the treated lesions ranged from 20 to 100 mm (mean 42.5; maximum of 4 tumor nodules). Tumor response was evaluated by computed axial tomography according to the World Health Organization criteria as modified by the European Association for the Study of Liver Diseases. All of the procedures were technically successful, and there were no major complications. At 1-month follow-up, complete tumor response was observed in 24 of 50 (48%), partial response in 18 of 50 (36%), and stable disease in 8 of 50 (16%) patients, and there were no cases of disease progression. At 6-month follow-up (31 of 50 patients), complete tumor response was obtained in 16 of 31 (51.6%), partial response in 8 of 31 (25.8%), and progressive disease in 7 of 31 (22.6%) patients. Within the initial 9-month follow-up, TACE with HepaSphere was successfully repeated twice in 3 patients, whereas 3 patients underwent the procedure 3 times. Our initial multicentre experience demonstrates that TACE using HepaSphere is feasible, is well tolerated, has a low complication rate, and is associated with promising tumor response. When complete tumor response in not achieved, additional treatments can be performed without difficulties. Longer follow-up on larger series is mandatory to confirm these preliminary results.
- 1 April 2005
- Published by Elsevier in The Journal of Emergency Medicine
- Vol. 28 (3) , 343-345
Massive hemoptysis in a young man
- 1 April 2005
- Published by Elsevier in The Journal of Emergency Medicine
- Vol. 28 (3) , 343-345
Massive hemoptysis in a young man